Joanna Stanislawiak

Dr. Joanna Stanislawiak


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2025 in Molecules
Verified
Journal Article
Open access
PDF file
AMAnna Markowska
Anna Markowska
JMJanina Markowska
Janina Markowska
JSJoanna Stanislawiak
Joanna Stanislawiak
KKKatarzyna Kozak
Katarzyna Kozak
OROtton Krzysztof Roubinek
Otton Krzysztof Roubinek
MJMagdalena Jasińska
Magdalena Jasińska
Ferulic acid (FA) is a polyphenol that is found in plants and fruits. It has a wide range of anticancer properties, including participating in cell apoptosis, inhibiting invasion and angiogenesis, and acting synergistically with standard cytostatic agents in malignant tumors. A range of molecular mechanisms are involved in anticancer activity and include the following ones: activation of cell-cycle-related proteins and enzymes such as p53, p21, Bax, and pro-caspases 3 and 9, reduction of cyclin D1 and E, proapoptotic Bcl-2, MMP-9, and NF-kV, which decrease VEGF, leading to cell cycle arrest at G0/G1 phase and death of cancer cells. Other mechanisms inhibit several pathways: PI3K/AKT/mTOR, Notch, and Wnt, which are associated with downregulation of proliferation, invasion, metastasis, and angiogenesis. FA can induce activation of ROS, leading to DNA damage in cancer cells. In vitro and in vivo studies have demonstrated the significant antitumor activity of FA in breast cancer, particularly when used in combination with cytostatic agents. In vitro studies on cervical cancer cell lines have reported similar anticancer activity of FA. This includes inhibition of cell proliferation and induction of apoptosis by downregulating antiapoptotic proteins. A case-control study conducted in Italy found that men with histologically confirmed prostate cancer had notably lower levels of FA compared to controls. Molecular in vitro studies have suggested that FA may have various effects on the signaling pathways linked to a reduction in the risk of prostate cancer, and it may act in synergy with δ-tocotrienol, which is a derivative of vitamin E. In vivo and in vitro studies on colorectal cancer have demonstrated the effects of FA on the early development of this cancer—inhibition of abnormal crypt foci (ACF-aberrant crypt foci), as well as the reduction in cancer cell viability and apoptosis through molecular changes, mainly a decrease in EGFR expression. The poor water solubility of FA makes it an attractive candidate for use as nanoparticles.

28 June 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AKAgnieszka Karbownik
Agnieszka Karbownik
DSDanuta Szkutnik-Fiedler
Danuta Szkutnik-Fiedler
Andrzej CzyrskiAndrzej Czyrski
Andrzej Czyrski
NKNatalia Kostewicz
Natalia Kostewicz
PKPaulina Kaczmarska
Paulina Kaczmarska
ESEdyta Szałek
Edyta Szałek
The tyrosine kinase inhibitor sorafenib is the first-line treatment for patients with hepatocellular carcinoma (HCC), in which hyperlipidemia and type 2 diabetes mellitus (T2DM) may often coexist. Protein transporters like organic cation (OCT) and multidrug and toxin extrusion (MATE) are involved in the response to sorafenib, as well as in that to the anti-diabetic drug metformin or atorvastatin, used in hyperlipidemia. Changes in the activity of these transporters may lead to pharmacokinetic interactions, which are of clinical significance. The study aimed to assess the sorafenib−metformin and sorafenib−atorvastatin interactions in rats. The rats were divided into five groups (eight animals in each) that received sorafenib and atorvastatin (ISOR+AT), sorafenib and metformin (IISOR+MET), sorafenib (IIISOR), atorvastatin (IVAT), and metformin (VMET). Atorvastatin significantly increased the maximum plasma concentration (Cmax) and the area under the plasma concentration–time curve (AUC) of sorafenib by 134.4% (p < 0.0001) and 66.6% (p < 0.0001), respectively. Sorafenib, in turn, caused a significant increase in the AUC of atorvastatin by 94.0% (p = 0.0038) and its metabolites 2−hydroxy atorvastatin (p = 0.0239) and 4−hydroxy atorvastatin (p = 0.0002) by 55.3% and 209.4%, respectively. Metformin significantly decreased the AUC of sorafenib (p = 0.0065). The AUC ratio (IISOR+MET group/IIISOR group) for sorafenib was equal to 0.6. Sorafenib did not statistically significantly influence the exposure to metformin. The pharmacokinetic interactions observed in this study may be of clinical relevance in HCC patients with coexistent hyperlipidemia or T2DM.

16 December 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AKAgnieszka Karbownik
Agnieszka Karbownik
DSDanuta Szkutnik-Fiedler
Danuta Szkutnik-Fiedler
TGTomasz Grabowski
Tomasz Grabowski
AWAnna Wolc
Anna Wolc
JSJoanna Stanislawiak
Joanna Stanislawiak
ESEdyta Szałek
Edyta Szałek
A combination of the tyrosine kinase inhibitor—sorafenib—and the opioid analgesic—morphine—can be found in the treatment of cancer patients. Since both are substrates of P-glycoprotein (P-gp), and sorafenib is also an inhibitor of P-gp, their co-administration may affect their pharmacokinetics, and thus the safety and efficacy of cancer therapy. Therefore, the aim of this study was to evaluate the potential pharmacokinetic drug–drug interactions between sorafenib and morphine using an animal model. The rats were divided into three groups that Received: sorafenib and morphine (ISOR+MF), sorafenib (IISOR), and morphine (IIIMF). Morphine caused a significant increase in maximum plasma concentrations (Cmax) and the area under the plasma concentration–time curves (AUC0–t, and AUC0–∞) of sorafenib by 108.3 (p = 0.003), 55.9 (p = 0.0115), and 62.7% (p = 0.0115), respectively. Also, the Cmax and AUC0–t of its active metabolite—sorafenib N-oxide—was significantly increased in the presence of morphine (p = 0.0022 and p = 0.0268, respectively). Sorafenib, in turn, caused a significant increase in the Cmax of morphine (by 0.5-fold, p = 0.0018). Moreover, in the presence of sorafenib the Cmax, AUC0–t, and AUC0–∞ of the morphine metabolite M3G increased by 112.62 (p < 0.0001), 46.82 (p = 0.0124), and 46.78% (p = 0.0121), respectively. Observed changes in sorafenib and morphine may be of clinical significance. The increased exposure to both drugs may improve the response to therapy in cancer patients, but on the other hand, increase the risk of adverse effects.

29 January 2025 in Pharmacological Reports
Verified
Journal Article
Closed access
PDF file
JSJoanna Stanislawiak
Joanna Stanislawiak
ESEdyta Szałek
Edyta Szałek
BWBarbara Więckowska
Barbara Więckowska
EGEdmund Grześkowiak
Edmund Grześkowiak
RMRadosław Mądry
Radosław Mądry

30 December 2021 in Oncology in Clinical Practice
Verified
Journal Article
Closed access
PDF file
JSJoanna Stanislawiak
Joanna Stanislawiak
ACAnita Chudecka-Głaz
Anita Chudecka-Głaz
MJMałgorzata Jazel
Małgorzata Jazel
RMRadosław Mądry
Radosław Mądry
The treatment of ovarian cancer based on platinum analogs has taken on a new and additional importance in recent years. The introduction of modern maintenance therapy — PARP inhibitors — has significantly prolonged the time to progression in recurrent and newly diagnosed ovarian cancer and clinically meaningful, as per SOLO-2 results, prolonging overall survival in recurrent disease. This is an absolute breakthrough in the treatment of advanced forms of this cancer. Sensitivity to platinum is a prerequisite for the efficacy of this therapy as well as patient eligibility for treatment. Hypersensitivity issues can significantly limit access to this modern and effective maintenance therapy. Platinum hypersensitivity usually occurs in subsequent lines of therapy and with subsequent cycles of treatment. Hypersensitivity reactions cannot always be predicted, despite known risk factors. In order to maintain platinum-based treatment, we can modify premedication modalities, but appropriate desensitization protocols seem to be most effective. This article describes the most commonly used desensitization methods in patients with ovarian cancer and platinum hypersensitivity in a practical way, e.g., as they are used in the centers where the authors of this publication practice. The treatment of ovarian cancer based on platinum analogs has taken on a new and additional importance in recent years. The introduction of modern maintenance therapy — PARP inhibitors — has significantly prolonged the time to progression in recurrent and newly diagnosed ovarian cancer and clinically meaningful, as per SOLO-2 results, prolonging overall survival in recurrent disease. This is an absolute breakthrough in the treatment of advanced forms of this cancer. Sensitivity to platinum is a prerequisite for the efficacy of this therapy as well as patient eligibility for treatment. Hypersensitivity issues can significantly limit access to this modern and effective maintenance therapy. Platinum hypersensitivity usually occurs in subsequent lines of therapy and with subsequent cycles of treatment. Hypersensitivity reactions cannot always be predicted, despite known risk factors. In order to maintain platinum-based treatment, we can modify premedication modalities, but appropriate desensitization protocols seem to be most effective. This article describes the most commonly used desensitization methods in patients with ovarian cancer and platinum hypersensitivity in a practical way, e.g., as they are used in the centers where the authors of this publication practice.